Meeting
2021 ASCO Annual Meeting
TNB585.001: A multicenter, phase 1, open-label, dose-escalation and expansion study of tnb-585, a bispecific T-cell engager targeting PSMA in subjects with metastatic castrate resistant prostate cancer.
Authors
Ben Buelow
TeneoBio, Inc., Menlo Park, CA
Ben Buelow , Pranjali Dalvi , Kevin Dang , Ashwin Patel , Kiran Johal , Duy Pham , Shailee Panchal , Yvonne Liu , Lawrence Fong , A. Oliver Sartor , Meredith McKean , Ute Schellenberger , Suhasini Iyer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Castrate-Resistant
Clinical Trial Registration Number
NCT04740034
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS5092)
DOI
10.1200/JCO.2021.39.15_suppl.TPS5092
Abstract #
TPS5092
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Susan F. Slovin
Poster
2018 ASCO Annual Meeting
A phase I study of 177Lu-DKFZ PSMA 617 combined with the radiosensitizer idronoxil in men with metastatic castrate-resistant prostate cancer (mCRPC) (LuPin trial).
First Author: Megan Crumbaker
Poster
2017 ASCO Annual Meeting
Phase 1 study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Michael J. Morris
Poster
2016 ASCO Annual Meeting
Phase 1 study of the PSMA-targeted tubulysin small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Michael J. Morris